After more than a month of speculation over how the FDA will rule on Novavax’s application for an updated formulation of its ...

Novavax posts $667 million in Q1 2025 revenue and $2.93 EPS, boosted by Sanofi payments and APA terminations; full-year ...

Vaccine maker Novavax stock jumped double digits on Thursday after the company reported its quarterly sales had more than ...

Wall Street’s major averages ended the week slightly lower on Friday, losing gains for the week amid renewed optimism about ...

Novavax posts encouraging first-quarter results on the back of an additional $603 million in revenues recognized from the ...

Novavax, Inc. (Nasdaq: NVAX) has updated the terms of the previously announced collaboration and licensing agreement (CLA) ...

Novavax highlighted that they believe their BLA for Nuvaxovid is approvable based on their conversations with the FDA to date and this additional data would be generated after BLA approval ...

The maker of the Nuvaxovid COVID shot delivered $666.7M in revenue for the quarter compared to $94M in the prior year period, surpassing analysts’ expectations by $322.8M. The company attributed ...

Sanofi Supply Sales Novavax will sell Nuvaxovid commercial supply to Sanofi for the 2025-2026 vaccination season and the reimbursement for this supply will be recorded as product sales.

The company noted that the improved financial terms of the amended agreement for the development, manufacturing and commercialization of Nuvaxovid in Japan include an upfront payment, payment ...

Nuvaxovid sales reached $608 million, up from $82 million a year ago. Cost of sales for the first quarter of 2025 was $14 million, compared to $59 million in the same period in 2024. R&D expenses ...

The improved financial terms of the amended agreement for the development, manufacturing and commercialization of Nuvaxovid® in Japan include an upfront payment, payment related to the 2024/2025 ...